Acquisition of Gracell completed
22 February 2024 Acquisition of Gracell completed AstraZeneca today announced the successful completion of the acquisition of Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering AstraZenecaÕs cell therapy ambition. The acquisition enriches AstraZenecaÕs growing